Phaseline

Targets › HCAR2

HCAR2 (Hydroxycarboxylic acid receptor 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Dec 2026.

Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. (UniProt, Q8TDS4)

Open in Phaseline: the race on HCAR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Indiana UniversityExtended Release Niacin
HCAR2 agonist
HCAR2Phase 1Alzheimer DiseaseDec 2026

Conditions

Alzheimer Disease (1)

Modalities

mixed (1)

Companies

Indiana University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.